Biocon shares surge on European approval path for Pertuzumab biosimilar

Shares of Indian biopharmaceutical company Biocon jumped during Monday's trading session after the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) issued a favorable recommendation for the company's Pertuzumab biosimilar drug.

The recommendation marks a significant milestone in Biocon's efforts to expand its presence in the European oncology market. Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer, a key segment in global cancer therapeutics.

The CHMP's positive opinion moves the biosimilar closer to formal European Union marketing authorization, a critical regulatory step for companies seeking to commercialize biologic drugs in European markets. The recommendation typically paves the way for final approval by the European Commission, though the timeline for such approval can vary.

Biocon has been strengthening its biosimilar portfolio in recent years as patents on several blockbuster biologics expire globally. The company's move into the Pertuzumab biosimilar space reflects its strategy to capture market share in high-value therapeutic areas, particularly in oncology where demand for more affordable biologic alternatives continues to grow.

The positive regulatory development comes as biosimilar adoption accelerates across Europe, driven by healthcare systems seeking cost-effective treatment options without compromising clinical efficacy.